Context Therapeutics Investor Presentation Deck
CLDN6 is an Emerging Oncology Target
XX
S
CLDN6xCD3 Bispecific Antibody Program
CLDN6 is a tumor-specific protein that is present at high surface density across adult and
pediatric cancers¹
CLDN6 selectivity is required to avoid off-target liabilities identified in murine knockout studies
with CLDN3 (pancreas), CLDN4 (kidney, pancreas), and CLDN9 (ear, gut)
BioNTech's BNT211 establishes Proof of Concept for CLDN6 immunotherapy:
5 of 10 (50% ORR) patients who received BNT211 (CLDN6 CAR-T) + CARVac (CLDN6
mRNA vaccine) showed a partial response in an ongoing Ph 1 study in CLDN6+ solid
tumors
Elevated transaminase and lipase were noted side effects²
16 Context Therapeutics Inc. - Sept. 2022
1 Faber MS, et al. Bispecific claudin-6 x CD3 antibodies AACR Annual Meeting; 2021; Virtual. Abstract 1860
2 Haanen JB, et al. BNT211: A Phase I trial. ESMO Annual Meeting; 2022; Paris, France. LBA38View entire presentation